CN105693731A - 巴瑞克替尼a晶型及其制备方法 - Google Patents
巴瑞克替尼a晶型及其制备方法 Download PDFInfo
- Publication number
- CN105693731A CN105693731A CN201610051264.9A CN201610051264A CN105693731A CN 105693731 A CN105693731 A CN 105693731A CN 201610051264 A CN201610051264 A CN 201610051264A CN 105693731 A CN105693731 A CN 105693731A
- Authority
- CN
- China
- Prior art keywords
- solvent
- buddhist nun
- ruike
- crystal formation
- ether
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Description
实施例 | 溶剂 | 收率 |
1 | 水 | 65% |
2 | 甲醇 | 61% |
3 | 乙醇 | 61% |
4 | 乙醚 | 60% |
5 | 异丙醚 | 66% |
6 | 正丙醇 | 64% |
实施例 | 溶剂种类 | 溶剂量 | 收率 |
19 | 水 | 5mL | 85% |
20 | 甲醇 | 3mL | 77% |
21 | 正丙醇 | 4mL | 76% |
22 | 异丙醇 | 6mL | 78% |
23 | 仲丁醇 | 8mL | 79% |
24 | 乙酸丁酯 | 10mL | 66% |
25 | 正庚烷 | 10mL | 86% |
26 | 正己烷 | 8mL | 85% |
27 | 环己烷 | 5mL | 88% |
28 | 丙酮 | 7mL | 73% |
29 | 乙醚 | 5mL | 88% |
30 | 异丙醚 | 7mL | 77% |
31 | 甲基叔丁基醚 | 10mL | 76% |
32 | 甲苯 | 8mL | 86% |
33 | 对二甲苯 | 10mL | 84% |
34 | 四氢呋喃 | 5mL | 76% |
35 | 二氯甲烷 | 3mL | 76% |
Claims (12)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610051264.9A CN105693731A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
CN201810481761.1A CN108383846A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610051264.9A CN105693731A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810481761.1A Division CN108383846A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105693731A true CN105693731A (zh) | 2016-06-22 |
Family
ID=56228594
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810481761.1A Pending CN108383846A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
CN201610051264.9A Withdrawn CN105693731A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810481761.1A Pending CN108383846A (zh) | 2016-01-26 | 2016-01-26 | 巴瑞克替尼a晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN108383846A (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3327020A1 (en) | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
WO2018113801A1 (en) | 2016-12-21 | 2018-06-28 | Zentiva, K.S. | Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation |
CN108341818A (zh) * | 2017-01-21 | 2018-07-31 | 南京华威医药科技开发有限公司 | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 |
WO2018233437A1 (zh) * | 2017-06-22 | 2018-12-27 | 苏州科睿思制药有限公司 | 巴瑞克替尼的晶型及其制备方法 |
CN109384792A (zh) * | 2018-11-06 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种球形巴瑞克替结晶的制备方法 |
CN109381437A (zh) * | 2018-11-06 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种巴瑞克替片剂组合物 |
EP3502114A1 (en) | 2017-12-20 | 2019-06-26 | Sandoz AG | Co-crystal of an orally available janus kinase inhibitor |
WO2019137325A1 (zh) * | 2018-01-09 | 2019-07-18 | 广东东阳光药业有限公司 | 巴瑞替尼磷酸盐的新晶型及其制备方法 |
WO2020163431A1 (en) | 2019-02-05 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Crystalline solid forms of baricitinib |
TWI781345B (zh) * | 2019-09-06 | 2022-10-21 | 台耀化學股份有限公司 | Baricitinib的結晶型與其製備方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115160221A (zh) * | 2022-07-26 | 2022-10-11 | 上海歆贻医药科技有限公司 | 德立替尼晶型化合物和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015145286A1 (en) * | 2014-03-28 | 2015-10-01 | Sun Pharmaceutical Industries Limited | Amorphous form of baricitinib |
WO2015166434A1 (en) * | 2014-05-01 | 2015-11-05 | Sun Pharmaceutical Industries Limited | Crystalline form of baricitinib |
-
2016
- 2016-01-26 CN CN201810481761.1A patent/CN108383846A/zh active Pending
- 2016-01-26 CN CN201610051264.9A patent/CN105693731A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015145286A1 (en) * | 2014-03-28 | 2015-10-01 | Sun Pharmaceutical Industries Limited | Amorphous form of baricitinib |
WO2015166434A1 (en) * | 2014-05-01 | 2015-11-05 | Sun Pharmaceutical Industries Limited | Crystalline form of baricitinib |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018099680A1 (en) | 2016-11-29 | 2018-06-07 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
EP3327020A1 (en) | 2016-11-29 | 2018-05-30 | Sandoz Ag | Citrate salts of a janus kinase (jak) inhibitor |
WO2018113801A1 (en) | 2016-12-21 | 2018-06-28 | Zentiva, K.S. | Crystalline forms of2-[1-ethylsulfonyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile with phosphoric acid and a method of their preparation |
CN108341818A (zh) * | 2017-01-21 | 2018-07-31 | 南京华威医药科技开发有限公司 | 巴瑞克替尼及其磷酸盐的新晶型及其制备方法 |
WO2018233437A1 (zh) * | 2017-06-22 | 2018-12-27 | 苏州科睿思制药有限公司 | 巴瑞克替尼的晶型及其制备方法 |
CN110799512A (zh) * | 2017-06-22 | 2020-02-14 | 苏州科睿思制药有限公司 | 巴瑞克替尼的晶型及其制备方法 |
WO2019121290A1 (en) | 2017-12-20 | 2019-06-27 | Sandoz Ag | Co-crystal of an orally available janus kinase inhibitor |
EP3502114A1 (en) | 2017-12-20 | 2019-06-26 | Sandoz AG | Co-crystal of an orally available janus kinase inhibitor |
WO2019137325A1 (zh) * | 2018-01-09 | 2019-07-18 | 广东东阳光药业有限公司 | 巴瑞替尼磷酸盐的新晶型及其制备方法 |
CN111278828A (zh) * | 2018-01-09 | 2020-06-12 | 广东东阳光药业有限公司 | 巴瑞替尼磷酸盐的新晶型及其制备方法 |
CN111278828B (zh) * | 2018-01-09 | 2021-08-31 | 广东东阳光药业有限公司 | 巴瑞替尼磷酸盐的新晶型及其制备方法 |
CN109381437A (zh) * | 2018-11-06 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种巴瑞克替片剂组合物 |
CN109384792A (zh) * | 2018-11-06 | 2019-02-26 | 威海贯标信息科技有限公司 | 一种球形巴瑞克替结晶的制备方法 |
WO2020163431A1 (en) | 2019-02-05 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Crystalline solid forms of baricitinib |
TWI781345B (zh) * | 2019-09-06 | 2022-10-21 | 台耀化學股份有限公司 | Baricitinib的結晶型與其製備方法 |
Also Published As
Publication number | Publication date |
---|---|
CN108383846A (zh) | 2018-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105693731A (zh) | 巴瑞克替尼a晶型及其制备方法 | |
CN105601635B (zh) | 巴瑞克替尼磷酸盐的a晶型、h晶型和i晶型及其制备方法 | |
CN107266453B (zh) | 作为蛋白激酶抑制剂的吡咯并嘧啶化合物 | |
CN104093398B (zh) | 7‑(6‑(2‑羟基丙烷‑2‑基)吡啶‑3‑基)‑1‑((反式)‑4‑甲氧基环己基)‑3,4‑二氢吡嗪并[2,3‑b]吡嗪‑2(1h)‑酮、其固体形式的药物组合物及其使用方法 | |
KR20160110518A (ko) | 염증 질환의 치료를 위한 신규의 염 및 그의 약학 조성물 | |
CN109311891B (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
EP3466958A1 (en) | New crystal form of sodium-glucose co-transporter inhibitor medicine and preparation method and use thereof | |
CN106008468B (zh) | 玻玛西尼a晶型、b晶型、c晶型及其制备方法 | |
CN104744445A (zh) | 一种酪氨酸激酶抑制剂的晶型 | |
CN105218539B (zh) | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 | |
CN107573348B (zh) | 巴瑞克替尼三氟乙酸盐b晶型及其制备方法 | |
CN105198947B (zh) | 一种Trifluridine化合物及其药物组合物 | |
CN105198880B (zh) | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 | |
WO2020098466A1 (zh) | 嘧啶并噻唑类杂环化合物,组合物及其治疗淋巴细胞白血病的用途 | |
CN105198877B (zh) | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 | |
CN105198879B (zh) | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 | |
CN114644642B (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
CN105111207B (zh) | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 | |
CN105198876B (zh) | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 | |
CN107868082A (zh) | 玻玛西尼甲磺酸盐a晶型及其制备方法 | |
EP4219476A1 (en) | Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof | |
CN105111206B (zh) | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 | |
CN105198878A (zh) | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 | |
CN113735859A (zh) | 一种激酶抑制剂 | |
Parsons et al. | An Improved Process for the Preparation of a Covalent Kinase Inhibitor through a C–N Bond-Forming SNAr Reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Ren Guobin Inventor after: Ge Dongxu Inventor after: Chen Jinyao Inventor before: Ren Guobin Inventor before: Ge Dongxu Inventor before: Chen Jinyao |
|
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 201207 Shanghai City, Pudong New Area Chinese (Shanghai) free trade zone fanchun Road No. 400 Building 1 layer 3 Applicant after: SHANGHAI XUANCHUANG BIOLOGICAL SCIENCE & TECHNOLOGY CO., LTD. Address before: 200072 Shanghai city Jiading District Fu Road No. 1011 A District 1309 room 3 Office Applicant before: SHANGHAI XUANCHUANG BIOLOGICAL SCIENCE & TECHNOLOGY CO., LTD. |
|
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160622 |